Clinical Experience with Ex Vivo Expansion of Haematopoietic Progenitor Cells.
Josy Reiffers, C. Cailliot, B. Dazey, I. McNiece, P. Duchez, A. Pigneux, J. Caraux, T. Cousin, B. Bussiere, J.M. Boiron
BMT Unit, CHU de Bordeaux, Pessac, France, Amgen SA, Paris; Dept of Cell Therapy, Blood Centre, ETSA, Bordeaux, France. University of Colorado HSC.
Autologous peripheral blood progenitor cell transplantation (PBPCT) has been shown to be capable of inducing earlier platelet and neutrophil recovery compared with bone marrow transplant (BMT), when rein fused after myeloablative chemotherapy.
Despite this reduction in the duration of aplasia, patients still experience approximately 10-12 days of aplasia, with all the associated risks of bleeding and/or infection. Over the past decade, various attempts have been made to increase the number and proliferative rate of hematopoietic cells before infusion, using controlled ex-vim culture with various cocktails of cytokines, and favorable results have been obtained in baboons.